Algernon Pharmaceuticals Inc.

Algernon is a clinical stage drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
Algernon has filed new intellectual property rights globally for its lead drug NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation.

Expert Comments:

Expert Clive Maund reviews the 6-month and 15-month charts for Awakn Life Sciences Corp. to explain why he thinks this company's technical setup is exceptionally positive.
read more >
One small-cap pharma co. just published more good news on a possible treatment for patients suffering from idiopathic pulmonary fibrosis, a lung disease that's usually terminal. Find out why the company has more near-term catalysts and may continue to build on an 84% gain since a private placement in mid-August.
read more >
Chris Temple
Expert Chris Temple gives his view on Algernon Pharmaceuticals stock in light of its positive results for its Phase 2a study for the treatment of idiopathic pulmonary fibrosis and chronic cough.
read more >
A Canadian hedge fund doubled its stake in a tiny biotech that demonstrated promising results in a study that used a former Sanofi drug called Ifenprodil to treat idiopathic pulmonary fibrosis and chronic cough. Find out the name of the company and why one analyst has given it a 12-month CA$25 target price — a 560% increase from the unit price in its recent placement.
read more >

Clive Maund,

"Algernon Pharmaceuticals Inc. announced the successful closing of its financing, which was oversubscribed. This will lift a restraint from the stock price. . .the company's largest shareholder has upped its stake significantly so that it now owns over 13% of the stock, which is of course a vote of confidence. . .so the case for buying Algernon here could scarcely be stronger. . .this is definitely a stock that is worth going overweight on."

read more >

Clive Maund,

"Given the bright fundamentals, Algernon Pharmaceuticals Inc.'s reaction earlier this week is thought to be about over. . .it is a good time to make fresh purchases as the company is rated Buy again here."

Clive Maund,

"There is a quite compelling reason to hold out for further gains with Algernon Pharmaceuticals Inc. . .with a relatively tiny number of shares in issue, now believed to be at 1.9M, the company has the capacity to make really big moves, such as occurred last January, which move we traded, so it could continue to spike higher, resistance or not."

read more >
read more >
A scientist at a junior biotech company recently conducted an additional review of the top line data from a Phase 2a study that used NP-120 to treat idiopathic pulmonary fibrosis (IPF) and chronic cough — only to learn that it treated chronic cough far better than first thought.
read more >

Clive Maund,

"Algernon Pharmaceuticals Inc. came out with very good news this morning that the data from its Phase 2 study of ifenprodil is much better than expected. This is thought likely to get the stock moving again, and so we are considered to be at another good buy spot here."

headshot of André Uddin

André Uddin, Research Capital Corporation

"After conducting additional statistical review of the Phase 2a data in idiopathic pulmonary fibrosis (IPF) patients with chronic cough, key opinion leader Dr. Jacky Smith noted that Algernon Pharmaceuticals Inc.'s cough data showed a significant improvement in mean objective 24-hour and waking cough counts after four and 12 weeks. . .it is our belief that it would be logical to develop ifenprodil for two indications: in IPF patients and also in IPF patients who have chronic cough."

Vancouver-based pharmaceutical development firm Algernon Pharmaceuticals Inc. recently reported topline data from a Phase 2a trial of ifenprodil in IPF patients with chronic cough that met its endpoint and demonstrated promising initial efficacy. Research Capital Corp. advised that it is maintaining its CA$25.00/share price target and "Speculative Buy" rating on the company.
read more >

André Uddin, Research Capital Corporation

"Algernon Pharmaceuticals Inc. reported topline results of a Phase 2a trial with ifenprodil in idiopathic pulmonary fibrosis (IPF) patients with chronic cough. The IPF data hit its endpoint, showing promising initial efficacy. . .we recommend investors with a higher risk tolerance to aggressively purchase the stock."

read more >

More Expert Comments

Experts Following This Company

Gerard Adams, President & CEO – National Inflation Association
Clive Maund –
headshot of Bob Moriarty
Bob Moriarty, Author – 321 Gold
headshot of Penny Queen
Penny Queen, Mother, Investor and Social Media Leader
headshot of Chris Temple
Chris Temple, Editor and Publisher – The National Investor
headshot of André Uddin
André Uddin – Research Capital Corporation

Company News 

9/21/2022 – Algernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund from Australian Research Program

9/19/2022 – Algernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for Ifenprodil as a Treatment of IPF

9/12/2022 – Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study

9/8/2022 – Algernon Pharmaceuticals Secures Lead Sponsorship of 2022 Wonderland Psychedelic Conference in Miami

9/1/2022 – Algernon Pharmaceuticals Reports Positive Results from Full Data Set of its Phase 2 Study of Ifenprodil for IPF and Chronic Cough

8/23/2022 – Algernon Pharmaceuticals' Largest Shareholder AlphaNorth Asset Management Increases Ownership Position

8/23/2022 – Algernon Pharmaceuticals Announces Closing of Private Placement

8/3/2022 – Algernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough Study Data at 9th American Cough Conference

7/28/2022 – Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study of Ifenprodil for IPF and Chronic Cough

7/18/2022 – Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough

7/11/2022 – Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study

7/7/2022 – Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study

7/5/2022 – Algernon Pharmaceuticals Discloses Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate and Pamoate

7/4/2022 – Algernon Pharmaceuticals Announces Closing of Public Offering of Units

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.See disclaimer for more details.

Investing Highlights
Advancing new drug treatments for billion dollar global disease markets.
Conducting multiple phase II clinical trials
Experienced management team & globally recognized medical advisory board
catalyst Calendar
U,S, FDA End-of-Phase 2 COVID-19 Study Meeting, Q2, 2021
Phase 2 trial for IPF and chronic cough data expected Q4, 2021.
Phase 1 Study planned for DMT, Q4 2021